Skip to main
BAX
BAX logo

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International has demonstrated positive momentum in its Healthcare Systems & Technologies segment, with year-over-year sales growth of approximately 6% in 1Q25 and 2% in 2Q25, indicating consistent demand for its medical supplies and equipment. The company's strategic acquisition of Hillrom has expanded its portfolio, enhancing its market position in hospital-focused offerings, complemented by recent pricing initiatives expected to contribute approximately 100 basis points of sales growth through 2025. While there are uncertainties regarding the sustainability of this growth as comparisons normalize in 2026, Baxter's robust performance and expanded product capabilities create a favorable outlook for the company.

Bears say

Baxter International's recent performance in 2Q25 showed a decline in sales, margins, and earnings per share (EPS), all falling short of consensus expectations, reflecting ongoing challenges for the company. Operational missteps experienced between 2021 and 2023 have contributed to mixed quarterly results and downward revisions in guidance, indicating deeper issues within the organization. Additionally, a notably low gross margin of 40.7%, compared to the consensus of 42.7%, coupled with an operating margin of 15.1%, which was over 100 basis points below expectations, signals significant inefficiencies and unfavorable product mix concerns.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.